As of 2025-03-19, the Relative Valuation of CytomX Therapeutics Inc (CTMX) is 6.64 USD. This relative valuation is based on P/E multiples. With the latest stock price at 0.60 USD, the upside of CytomX Therapeutics Inc based on Relative Valuation is 999.1%.
The range of the Relative Valuation is 3.79 - 9.08 USD.
| Range | Selected | |
| Trailing P/E multiples | 13.6x - 19.1x | 16.5x |
| Forward P/E multiples | 8.9x - 21.3x | 15.4x |
| Fair Price | 3.79 - 9.08 | 6.64 |
| Upside | 528.6% - 1403.8% | 999.1% |
| Date | P/E |
| 2025-03-18 | 1.47 |
| 2025-03-17 | 1.55 |
| 2025-03-14 | 1.60 |
| 2025-03-13 | 1.45 |
| 2025-03-12 | 1.47 |
| 2025-03-11 | 1.52 |
| 2025-03-10 | 1.64 |
| 2025-03-07 | 1.63 |
| 2025-03-06 | 1.52 |
| 2025-03-05 | 1.51 |
| 2025-03-04 | 1.60 |
| 2025-03-03 | 1.60 |
| 2025-02-28 | 1.66 |
| 2025-02-27 | 1.66 |
| 2025-02-26 | 1.67 |
| 2025-02-25 | 1.70 |
| 2025-02-24 | 1.83 |
| 2025-02-21 | 1.92 |
| 2025-02-20 | 2.00 |
| 2025-02-19 | 1.97 |
| 2025-02-18 | 1.95 |
| 2025-02-14 | 1.96 |
| 2025-02-13 | 2.03 |
| 2025-02-12 | 1.95 |
| 2025-02-11 | 1.86 |
| 2025-02-10 | 1.94 |
| 2025-02-07 | 2.06 |
| 2025-02-06 | 2.14 |
| 2025-02-05 | 2.30 |
| 2025-02-04 | 2.12 |
| 2025-02-03 | 2.06 |
| 2025-01-31 | 2.09 |
| 2025-01-30 | 2.15 |
| 2025-01-29 | 2.01 |
| 2025-01-28 | 2.09 |
| 2025-01-27 | 2.13 |
| 2025-01-24 | 2.19 |
| 2025-01-23 | 2.13 |
| 2025-01-22 | 2.06 |
| 2025-01-21 | 2.14 |
| 2025-01-17 | 2.06 |
| 2025-01-16 | 2.08 |
| 2025-01-15 | 2.11 |
| 2025-01-14 | 2.07 |
| 2025-01-13 | 2.18 |
| 2025-01-10 | 2.16 |
| 2025-01-08 | 2.41 |
| 2025-01-07 | 2.50 |
| 2025-01-06 | 2.80 |
| 2025-01-03 | 2.77 |